ArticleWorld journal of urology2025
Effects of antifibrotic agent Nintedanib on experimentally generated priapism model in rats.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study investigated the effects of Nintedanib, a triple tyrosine kinase inhibitor, on cavernosal tissues in a rat model of ischemic priapism (IP), focusing on fibrosis and erectile function.
methodsSixty male Wistar Albino rats were divided into five groups (n = 12): Group 1 (control), Group 2 (1-hour IP + penectomy), Group 3 (1-hour IP + 6-week follow-up), Group 4 (1-hour IP + Nintedanib treatment for 6 weeks), and Group 5 (Nintedanib only). Erectile function was evaluated via intracavernosal pressure (ICP) during nerve stimulation. Fibrosis was assessed using Masson's trichrome staining and immunohistochemistry for VEGFR-2, PDGFR-β, and FGF-1. Oxidative stress markers (MDA, GSH, SOD) and growth factors were analyzed via ELISA and spectrophotometry. Statistical analysis used Kruskal-Wallis and Mann-Whitney U tests (p < 0.05).
resultsGroup 4 had significantly lower mean intracavernosal pressure (MeICP) values (median 26.5 mmHg) than Group 3 (49 mmHg) (p < 0.001). Masson's trichrome showed highest fibrosis in Group 4 (score 3 [2-4]) compared to Group 3 (score 3 [1-4]) (p < 0.001). VEGFR-2 ELISA levels dropped in Group 4 (6.55 ng/mL [5.5-7.1]) vs. Group 3 (7.75 ng/mL [7-7.9]) (p < 0.001). MDA levels peaked in Group 4 (33.66 nmol/g [24.39-45.39]), while GSH values remained comparable between Groups 3 and 4. SOD increased significantly in Groups 2-4 (Group 4: 6.25 ng/mL [5.2-7.0]) compared to Group 1 (4.95 ng/mL [3.9-5.6]) (p < 0.001).
conclusionAlthough Nintedanib is antifibrotic in pulmonary contexts, it appears to promote penile fibrosis post-IP, likely via excessive VEGFR-2 inhibition, impairing vascular recovery and erectile function. Further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.